Latest filingSep 09, 2026Most recent Form 4
URGN
UroGen Pharma Ltd.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$295M3 sells
Net open-market-$295M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period9transactions
- M · Option exercise · dominant6 · 67%
- S · Open-market sells3 · 33%
Activity by reported role
A joint filing can contribute to multiple roles9transactions
- CMO · dominant4 · 44%
- GC3 · 33%
- Director2 · 22%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeSmith Jason DrewOrdinary Shares · Direct
53,141Sep 08, 2026
Schoenberg MarkOrdinary Shares · Direct
59,882Sep 08, 2026
Schoenberg Markordinary shares · Direct
59,086Aug 20, 2026
Robinson James A. Jr.ordinary shares · Direct
8,000Aug 26, 2026
Robinson James A. Jr.Restricted Stock Unit · Direct
0Aug 26, 2026
Smith Jason DrewRestricted Stock Units · Direct
0Sep 07, 2026
Schoenberg MarkRestricted Stock Units · Direct
0Sep 07, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- SM-$2.9M
- SD-$64.6k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
URGN transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| URGN | Schoenberg Mark | CMO | sale | 871 | -$3.73M | S | — | 0.0% | 09/09 | 09/08 |
| URGN | Smith Jason Drew | GC | sale | 1.51k | -$6.46M | S | — | 0.0% | 09/09 | 09/08 |
| URGN | Schoenberg Mark | CMO | sale | 60.6k | -$285M | S | −0.8% | 08/24 | 08/20 |
UroGen Pharma Ltd. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at UroGen Pharma Ltd.?
Schoenberg Mark, Smith Jason Drew, Robinson James A. Jr..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Schoenberg Mark reported a sale on Sep 08, 2026 valued at $3.73M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $2,956,854.43. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.